CAS 870281-82-6
:Idelalisib
Description:
Idelalisib is a selective inhibitor of phosphoinositide 3-kinase (PI3K) delta, primarily used in the treatment of certain types of hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and follicular lymphoma. Its chemical formula is C19H19ClN2O4S, and it features a chlorobenzene ring, a pyrimidine moiety, and a sulfonamide group, which contribute to its pharmacological activity. Idelalisib works by disrupting the signaling pathways that promote cell proliferation and survival in malignant B cells. The substance is administered orally and is known for its potential side effects, including diarrhea, liver function abnormalities, and immune-related adverse events. As a targeted therapy, idelalisib represents a significant advancement in the treatment of specific cancers, offering a more focused approach compared to traditional chemotherapy. Its development underscores the importance of molecular targeting in oncology, aiming to improve patient outcomes while minimizing systemic toxicity.
Formula:C22H18FN7O
InChI:InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
InChI key:InChIKey=IFSDAJWBUCMOAH-HNNXBMFYSA-N
SMILES:[C@H](NC1=C2C(N=CN2)=NC=N1)(CC)C=3N(C(=O)C=4C(N3)=CC=CC4F)C5=CC=CC=C5
Synonyms:- (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
- 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-
- 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-
- 5-Fluoro-3-Phenyl-2-[(1S)-1-(9H-Purin-6-Ylamino)Propyl]-4(3H)-Quinazolinone
- Cal-101
- Delalisib
- Gs-1101
- Idelalisib
- N<sup>6</sup>-[(S)-1-(5-Fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl]adenine
- Zydelig
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 11 products.
4(3H)-Quinazolinone,5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-
CAS:Formula:C22H18FN7OPurity:98%Color and Shape:SolidMolecular weight:415.4230Ref: IN-DA00GU21
1g157.00€5g337.00€25gTo inquire50gTo inquire100gTo inquire10mg35.00€50mg41.00€100mg57.00€250mg81.00€5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone
CAS:<p>5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone</p>Purity:98%Molecular weight:415.42g/molIdelalisib
CAS:Idelalisib (GS-1101) is a small molecule inhibitor of the PI3K catalytic subunit p110δ (IC50: 2.5 nM).Formula:C22H18FN7OPurity:98% - 99.39%Color and Shape:SolidMolecular weight:415.42CAL-101
CAS:Controlled Product<p>Applications CAL-101 is a PI3K/mTOR pathway inhibitor used in the treatment of myeloid leukemia through sensitizing the cells to combatting drugs. Potent PI3K-p110-delta inhibitor.<br>References Airiau, K. et al.: Cell. Death. Dis., 4, e827 (2013); Kulesz-Martin, M. et al Canc. Biol. Ther., 14m 95 (2013);<br></p>Formula:C22H18FN7OColor and Shape:Light BrownMolecular weight:415.40Idelalisib
CAS:<p>Idelalisib is a pharmaceutical drug that functions as a PI3Kδ inhibitor, developed through synthetic chemical processes. Its mode of action involves selectively targeting and inhibiting phosphatidylinositol 3-kinase delta (PI3Kδ), a lipid kinase that plays a crucial role in the signaling pathways responsible for cell proliferation, survival, and differentiation. By inhibiting this enzyme, Idelalisib effectively impedes pathways that are often hyperactivated in certain hematologic malignancies, thereby exerting antitumor effects.</p>Formula:C22H18FN7OPurity:Min. 95%Color and Shape:PowderMolecular weight:415.42 g/mol(S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
CAS:Purity:95.0%Color and Shape:SolidMolecular weight:415.4320068359375







